|
NID1 expression based on
|
Statistics: Unpaired two sample T-test was employed to evaluate levels of significance in expression level between any two sample groups
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
1.22019949699848E-10 |
| Normal-vs-Stage3 |
1.93178806284777E-14 |
| Normal-vs-Stage4 |
1.98670002671264E-09 |
| Stage1-vs-Stage2 |
9.323200E-01 |
| Stage1-vs-Stage3 |
4.839400E-01 |
| Stage1-vs-Stage4 |
2.090400E-01 |
| Stage2-vs-Stage3 |
5.432000E-01 |
| Stage2-vs-Stage4 |
2.577600E-01 |
| Stage3-vs-Stage4 |
5.253000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
6.211700E-04 |
| Normal-vs-Asian |
2.53120002735585E-09 |
| Caucasian-vs-AfricanAmerican |
3.686000E-01 |
| Caucasian-vs-Asian |
5.415200E-01 |
| AfricanAmerican-vs-Asian |
2.722000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
<1E-12 |
| Male-vs-Female |
8.122100E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62458935193399E-12 |
| Normal-vs-Age(41-60Yrs) |
1.62458935193399E-12 |
| Normal-vs-Age(61-80Yrs) |
1.71684888528034E-12 |
| Normal-vs-Age(81-100Yrs) |
1.184110E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.739800E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.920400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.213600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.296350E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.281200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.916800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.008600E-01 |
| Classical-VS-Follicular |
1.040070E-04 |
| Classical-VS-Other |
3.027000E-01 |
| Classical-VS-Normal |
<1E-12 |
| Tall-VS-Follicular |
2.901200E-03 |
| Tall-VS-Other |
1.619620E-01 |
| Tall-VS-Normal |
2.50499998522002E-09 |
| Follicular-VS-Other |
9.820600E-01 |
| Follicular-VS-Normal |
1.62836411021772E-12 |
| Other-VS-Normal |
3.258400E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.62447832963153E-12 |
| Normal-vs-N1 |
3.66809915774979E-11 |
| N0-vs-N1 |
3.975600E-02 |
|
|
